Isis Lipid-Lowering Candidate Named Mipomersen; Firm Projects Smaller Loss
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm revises net operating loss guidance downward by roughly $20 million.
You may also be interested in...
Genzyme/Isis: Has ENHANCE Dulled Mipomersen's Prospects?
In early January, Genzyme nabbed one of the highest-value specialist cholesterol-busting drugs around: Phase III mipomersen, from Isis Pharmaceuticals. But given the ENHANCE-triggered questions around the value of ever-lower LDL, it's reasonable to ask whether mipomersen has a somewhat less rosy prospect in the few weeks since the deal was signed.
Isis Spin-Off Altair Will Develop Antisense Asthma Candidate 369645
Isis uses “satellite” strategy to focus internal development on cardiovascular, metabolic disease candidates, including mipomersen, while expanding therapeutic indications for its antisense drugs.
Isis Spin-Off Altair Will Develop Antisense Asthma Candidate 369645
Isis uses “satellite” strategy to focus internal development on cardiovascular, metabolic disease candidates, including mipomersen, while expanding therapeutic indications for its antisense drugs.